Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
176
NCT01077908
Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study
Phase: Phase 3
Role: Lead Sponsor
Start: Jul 31, 2008
Completion: Oct 31, 2014
NCT01220895
Alternate Donor Study of Pre-Emptive Cellular Therapy
Phase: Phase 2
Start: Oct 31, 2010
Completion: Jan 31, 2014
NCT01621724
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
Phase: Phase 1/2
Start: Apr 30, 2012
Completion: May 31, 2018
NCT01822093
Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT
Start: Dec 31, 2012
Completion: Dec 31, 2016
NCT01948180
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
Start: Sep 30, 2014
Completion: Sep 7, 2018
NCT02550535
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Start: Sep 30, 2015
NCT02873325
Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT
Phase: N/A
Start: May 11, 2016
Completion: Feb 23, 2017
NCT02763254
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
Start: Nov 30, 2016
Completion: Feb 17, 2018